Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Arpida files iclaprim in Canada

This article was originally published in Scrip

Executive Summary

Arpidahas filed its lead product, the intravenous antibiotic iclaprim, for approval in Canada. The filing is for the treatment of complicated skin and skin structure infection (cSSSI) and includes data from the ASSIST-1 and ASSIST-2 Phase III trials, which showed iclaprim was non-inferior to Pfizer's Zyvox (linezolid) for cSSSI in a group of patients with a high incidence of meticillin-resistant Staphylococcus aureus (MRSA). Iclaprim is a synthetic diaminopyrimidine and Arpida has said it believes the compound may have benefits over Zyvox, an oxazolidinone antibiotic which can cause myelosuppression. The company filed for approval of iclaprim in the US in March and in the EU in July (Scrip Online, March 20th, 2008 and Scrip Online, July 29th, 2008, respectively).

Advertisement
Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC003165

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel